肿瘤细胞治疗研究
英文原题：The emerging role of tafasitamab in follicular lymphoma.
滤泡性淋巴瘤（FL）是最常见的惰性 B 细胞非霍奇金淋巴瘤，其特征为反复复发、组织学转化风险以及异质性临床结局。
滤泡性淋巴瘤（FL）是最常见的惰性B细胞非霍奇金淋巴瘤，特点是反复复发、存在组织学转化风险且临床结局异质性高。尽管新型疗法不断进展，复发/难治性FL管理仍具挑战。人源化抗CD19单克隆抗体tafasitamab目前已获批联合来那度胺治疗复发/难治性弥漫大B细胞淋巴瘤（DLBCL），并联合来那度胺和利妥昔单抗治疗R/R FL。临床试验数据支持其治疗FL（包括首次复发患者）的疗效和可管理安全性，也适用于POD24和CD20难治等高危亚组。这种无化疗方案具有良好安全性，可补充CAR-T细胞或双特异性抗体等更复杂疗法。仍需进一步研究明确tafasitamab获益的持久性、最佳治疗顺序及其在不断变化的FL治疗格局中的整合方式。
Follicular lymphoma (FL) is the most common indolent B-cell non-Hodgkin lymphoma, characterized by recurrent relapses, risk of histologic transformation, and heterogeneous clinical outcomes. Despite advances with novel therapies, the management of relapsed/refractory FL remains challenging. Tafasitamab, a humanized anti-CD19 monoclonal antibody, is currently approved, in combination with lenalidomide, for relapsed refractory (R/R) diffuse large B-cell lymphoma (DLBCL), and together with lenalidomide and rituximab for R/R FL. Clinical trial data support its efficacy and manageable safety profile in FL starting from fisrt relapse, including in high-risk FL subgroups such as early relapse (POD24) and CD20-refractory disease. This chemotherapy-free regiment is added with its favorable safety profile to more complex therapies such as CAR T-cell therapy or bispecific antibodies. Further studies are needed to clarify tafasitamab's durability of benefit, optimal sequencing, and integration within the evolving FL treatment landscape.
MEMBER ACCOUNT
登录成功会直接打开下一页。
